AR050921A1 - Heterociclos fusionados seleccionados y usos de los mismos - Google Patents

Heterociclos fusionados seleccionados y usos de los mismos

Info

Publication number
AR050921A1
AR050921A1 ARP050103462A ARP050103462A AR050921A1 AR 050921 A1 AR050921 A1 AR 050921A1 AR P050103462 A ARP050103462 A AR P050103462A AR P050103462 A ARP050103462 A AR P050103462A AR 050921 A1 AR050921 A1 AR 050921A1
Authority
AR
Argentina
Prior art keywords
methyl
propyl
benzamide
pyrimidin
dihydro
Prior art date
Application number
ARP050103462A
Other languages
English (en)
Inventor
Brian Aquila
Michael Block
Audrey Davies
Jayachandran Ezhuthachan
Timothy Pontz
Daniel Russell
Xiaolan Zheng
Marie-Elena Theoclitou
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35004223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050921(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR050921A1 publication Critical patent/AR050921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

Composiciones farmacéuticas que los contienen y usos para la profilaxis del cáncer. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), que incluye una sal aceptable para uso farmacéutico del mismo, en donde: X se selecciona entre C o S con la salvedad de que cuando X es S entonces Y es C; Y se selecciona entre C o O o S con la salvedad de que cuando Y es C entonces X no es C; m es 0, o 1; R1 es F, cuando m es 1; R2 se selecciona entre C1-3 alquilo; n es 2 o 3; R3 y R4 se seleccionan en forma independiente entre H o C1-2 alquilo; R5 se selecciona entre F, Cl, Br, o C1-2 alquilo; p es 1 o 2; se selecciona entre: N-(3-amino-propil)-N-{1-[5-(3-fluoro-bencil)-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4- d]pirimidin-6-il]-propil}-4-metil-benzamida; N-(3-amino-propil)-N-{1-[5-(3-fluoro-bencil)-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il]-2-meil-propil}-4-metil-benzamida; N-(2-amino-etil)-N-[1-(5-bencil-3-metil-4-oxo-4,5-dihidro- isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-4-bromo-benzamida; N-(2-amino-etil)-N-[1-(5-bencil-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-4-metil-benzamida; N-(2-amino-etil)-N-[1-(5-bencil-3-metil-4-oxo-4,5- dihidro-isotiazolo[5,4-d]pirimidin-6-il]-2-metil-propil]-3-fluoro-4-metil-benzamida; N-(3-amino-propil)-N-[1-(5-bencil-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-3-fluoro-4-metil-benzamida; N-(3-amino-propil)-N-[1-(5- bencil-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-4-bromo-benzamida; N-[1-(5-bencil-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-N-(3-dimetilamino-propil)-4-metil-benzamida; N-[1-(5- bencil-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-N-(3-dimetilamino-propil)-4-bromo-benzamida; N-[1-(5-bencil-3-metil-4-oxo-4,5-dihidro-isotiazolo[5,4-d]pirimidin-6-il)-2-metil-propil]-N-(3-dimetilamino-propil)-3- fluoro-4-metil-benzamida; N-(3-amino-propil)-N-{1-[5-(3-fluoro-bencil)-3-metil-4-oxo-4,5-dihidro-isoxazolo[5,4-d]pirimidin-6-il]-2-metil-propil}-4-metil-benzamida; N-(3-amino-propil)-N-[1-(6-bencil-3-metil-7-oxo-6,7-dihidro-isotiazolo[4,5- d]pirimidin-5-il)-propil]-4-metil-benzamida.
ARP050103462A 2004-08-18 2005-08-16 Heterociclos fusionados seleccionados y usos de los mismos AR050921A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60239904P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
AR050921A1 true AR050921A1 (es) 2006-12-06

Family

ID=35004223

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103462A AR050921A1 (es) 2004-08-18 2005-08-16 Heterociclos fusionados seleccionados y usos de los mismos

Country Status (19)

Country Link
US (1) US20070249636A1 (es)
EP (1) EP1781673B1 (es)
JP (1) JP2008509976A (es)
KR (1) KR20070046175A (es)
CN (1) CN101023086A (es)
AR (1) AR050921A1 (es)
AT (1) ATE446301T1 (es)
AU (1) AU2005273704A1 (es)
BR (1) BRPI0514398A (es)
CA (1) CA2575056A1 (es)
DE (1) DE602005017283D1 (es)
IL (1) IL180811A0 (es)
MX (1) MX2007001954A (es)
NO (1) NO20070980L (es)
RU (1) RU2007109867A (es)
TW (1) TW200621260A (es)
UY (1) UY29074A1 (es)
WO (1) WO2006018627A1 (es)
ZA (1) ZA200701081B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2447077C2 (ru) 2004-08-18 2012-04-10 Астразенека Аб Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
JP2008546843A (ja) * 2005-06-27 2008-12-25 アムゲン インコーポレイティッド 抗炎症性アリールニトリル化合物
RU2521333C2 (ru) * 2007-06-21 2014-06-27 Ньюронасент, Инк. Способы и композиции для стимулирования нейрогенеза и ингибирования дегенерации нейронов с использованием изотиазолопиримидинонов
DK2194987T3 (en) 2007-09-10 2016-08-15 Boston Biomedical Inc Newly known group of stat3 signaling pathway inhibitors and cancer stem cell inhibitors
BRPI0818605A2 (pt) 2007-10-19 2015-04-22 Schering Corp Derivados de 1,3,4-tiadiazl espiro-condensados para inibir a atividade de ksp cinesima
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363960B2 (en) * 2001-12-06 2008-07-10 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
DE60234278D1 (de) * 2001-12-06 2009-12-17 Merck & Co Inc Mitotische kinesin-hemmer
US6924376B2 (en) * 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
WO2004078758A1 (en) * 2003-03-07 2004-09-16 Astrazeneca Ab Novel fused heterocycles and uses thereof
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents

Also Published As

Publication number Publication date
WO2006018627A1 (en) 2006-02-23
CA2575056A1 (en) 2006-02-23
IL180811A0 (en) 2007-06-03
RU2007109867A (ru) 2008-09-27
MX2007001954A (es) 2007-05-09
US20070249636A1 (en) 2007-10-25
BRPI0514398A (pt) 2008-06-10
DE602005017283D1 (de) 2009-12-03
KR20070046175A (ko) 2007-05-02
ZA200701081B (en) 2008-08-27
CN101023086A (zh) 2007-08-22
ATE446301T1 (de) 2009-11-15
UY29074A1 (es) 2006-03-31
EP1781673B1 (en) 2009-10-21
EP1781673A1 (en) 2007-05-09
JP2008509976A (ja) 2008-04-03
TW200621260A (en) 2006-07-01
NO20070980L (no) 2007-03-12
AU2005273704A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
AR050921A1 (es) Heterociclos fusionados seleccionados y usos de los mismos
ATE369370T1 (de) Substituierte 2h-(1,2,4)triazolo(4,3-a)pyrazine als gsk-3-inhibitoren
PA8603801A1 (es) Derivados de la quinazolina
DE59812455D1 (de) Fluorpyrazol-biphenylamide als fungizide
BR0316152A (pt) Compostos de pirimidina
BRPI0407827A (pt) compostos de aminoeteroarila como inibidores de proteìna cinase
RU2447077C2 (ru) Энантиомеры выбранных конденсированных пиримидинов и их применение для лечения и предотвращения злокачественного новообразования
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
HRP20041166B1 (hr) Pirazolopiridini supstituirani s karbamatom
AR035974A1 (es) Derivados de diarilmetil piperazina, procesos para su preparacion, uso de estos derivados para la elaboracion de medicamentos y composicion farmaceutica
EA200501333A1 (ru) 5,7-ДИАМИНОПИРАЗОЛО[4,3-d]ПИРИМИДИНЫ, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ ГИПЕРТЕНЗИИ
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
MA27711A1 (fr) Derives de pyrazolo [1,5-a] pyrimidine
ME00116B (me) Piperazin sa ili supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
ECSP066541A (es) Nuevos derivados de piridazin-3(2h)-ona
UY27516A1 (es) Bencimidazoles
SV1999000251A (es) Derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina ref. pcl0085/82805/bb
GT199900150A (es) 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas.
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
SE0302324D0 (sv) Novel compounds
BR0107770A (pt) Derivados de 3-fenóxi-1-fenil acetileno e seu uso como herbicidas
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer

Legal Events

Date Code Title Description
FB Suspension of granting procedure